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Abstract. Radiation-induced cranial nerve palsy (RICNP) 
is a severe long-term complication in patients with head and 
neck cancer following high-dose radiation therapy (RT). We 
present the case report of a patient with bilateral RICNP of 
the hypoglossal and vagus cranial nerves (XII/X) following 
postoperative RT in the era prior to the introduction of 
intensity-modulated RT (IMRT), and an analysis of our IMRT 
patient cohort at risk including the case of a XII RICNP. A 
total of 201 patients whose glosso-pharyngeal (IX), X and XII 
cranial nerves had been exposed to >65 Gy definitive IMRT 
in our institution between January, 2002 and December, 2012 
with or without systemic therapy, were retrospectively identi-
fied. A total of 151 patients out of 201 fulfilling the following 
criteria were included in the analysis: Locoregionally 
controlled disease, with a follow-up (FU) of >24 months and 
>65 Gy exposure of the nerves of interest. So far, one of the 
assessed 151 IMRT patients at risk exhibited symptoms of 
RICNP after 6 years. The mean/median FU of the entire cohort 
was  71/68 months (range, 27-145). The results were compared 
with literature reports. In conclusion, RICNP appears to be a 
rare complication. However, a longer FU and a larger sample 
size are required to draw reliable conclusions on the incidence 
of RICNP in the era of IMRT.
Introduction
Radiation-induced cranial nerve palsy (RICNP) is a severe 
long-term effect observed in patients treated with high-dose 
radiation therapy (RT) for nasopharyngeal carcinoma, with an 
incidence ranging between 3.7 and 30.9% in the literature (1-9).
Several studies have reported that the lower cranial 
nerves (CNs) are more susceptible to radiation damage (1-3). 
RICNP significantly compromises the quality of life: Damage 
of the glossopharyngeal nerve (IX) causes loss of sensation 
in the pharynx and decreased salivation; palsy of the vagus 
nerve (X) leads to impaired parasympathetic functions of 
almost all organs; and palsy of the hypoglossal nerve (XII) 
causes complete paralysis of the ipsilateral side of the tongue.
The aim of this study was to present the detailed clinical 
findings of two patients with RICNP following conventional 
three-dimensional (3D) RT and IMRT, respectively, and to 
analyze the IMRT cohort at risk (high radiation dose delivered 
to the upper level 2 and 7b lymph node stations, where the 
nerves IX-XII pass through), in order to assess the incidence of 
RICNP in IMRT.
Case reports
Case report 1 (3D‑RT). In June 1999, a 50-year-old male 
patient was referred to our department for postoperative RT for 
a squamous cell carcinoma of the right tonsil with unilateral 
lymph node metastases, staged as pT3 (4.2 cm), pN2b (1/29, 
Rouvière node), M0, R0 (minimal resection margin, 2 mm), 
G3.
The patient had previously undergone trans-cervical 
oropharyngectomy with neck dissection of ipsilateral level 1-3 
lymph nodes. Reconstruction of the defect was performed with 
a free radialis flap.
RT planning was performed using a computed tomography 
(CT)-based 3D conformal radiation technique. Adjuvant RT 
was performed according to the following concomitant boost 
(CCB) schedule: A first series with 20x1.8 to a total of 36 Gy 
using laterally opposed photon beams, followed by spinal cord 
sparing electrons to the dorsal lymphatic pathways combined 
with anterior lateral opposed photon beam to a total of 50.4 Gy. 
The CCB was performed with 9x1.5 Gy as a 2nd fraction/day, 
once/week. Unfortunately, the electron isodose distribution is 
no longer available, as the former treatment planning system has 
been replaced by other systems. In an attempt to reconstruct the 
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dose to the nerve region of interest (ROI) in this patient based 
on hard copy printouts from 1999, bilateral high-dose expo-
sure was documented, as the primary lesion extended to both 
sides and there was significant nodal disease. The XII nerve 
was bilaterally exposed to the tumor dose, except for the most 
cranial aspect (2-3 cm from the hypoglossal canal), which was 
exposed to a lower dose (~50-55 Gy), which is usually well 
tolerated (Fig. 1). The patient underwent regular follow-up 
(FU) at our joint Otorhinolaryngology clinic (S.S., G.H.) until 
July, 2000. Late term tolerance to treatment has been good 
thus far, apart from a velopalatal insufficiency due to extensive 
palatal resection with consequent altered speech. Velopalatal 
reconstructive surgery was performed in July, 2000.
In May, 2011, the patient developed swallowing distur-
bances due to impaired tongue and laryngeal movement. 
Sufficient nutrition was ensured through a feeding tube. In 
June, 2011 the patient underwent transcervical cricomyotomy 
to reduce the resistance to swallowing, which achieved a 
minor improvement. At that time, bilateral XII nerve palsy 
was diagnosed. Centrally located causes, such as amyotrophic 
lateral sclerosis, were excluded. Following re-evaluation of the 
RT fields, XII nerve palsy was hypothesized to be a side effect 
of the bilateral irradiation 12 years prior.
Further extensive neurological and radiological investiga-
tions were performed to differentiate between RT-induced 
damage vs. other causes, which revealed an overall decreased 
motor neuron activity affecting other nerves, including the 
tibial and median nerves; to a certain extent, the progressive 
severe symptoms were considered to reflect the coexistence 
of radiation-related and independent neuronal disorders. 
However, in August, 2014, the patient was diagnosed with 
bilateral X nerve paresis with nocturnal stridor, feeding tube 
dependency and almost completely paralyzed tongue muscles, 
which supported the radiogenic etiology of the symptoms. To 
date, the patient remains tumor-free (September, 2014).
Care report 2 (IMRT). A 46-year-old patient underwent 
definitive SIB-IMRT with 30x2.2 Gy/fraction (66 Gy mean 
dose) for a left-sided cT1cN1 base of tongue carcinoma. 
Six years later he was diagnosed with an ipsilateral brachial 
plexopathy, which was due to a disc herniation C3/4 and C5/6, 
and a left XII nerve RICNP grade 2-3, for which other etiology 
with the exception of RT was excluded. The 2.2 Gy/f SIB-IMRT 
schedule was used for several other patients in the initial 
IMRT implementation phase. The Dmax point dose in this 
patient was 74 Gy (Fig. 3). Two years later, the patient 
Figure 2. Contoured nerve region of interest (yellow outline) and planning 
target volume (red-shaded area). ROI, region of interest.
Figure 3. Case with left sided XII palsy 6 years post IMRT: depicted is the 
dose volume treated with 66-74 Gy in 30 fractions using simultaneously 
integrated boost (SIB).
Figure 1. Case report. (A) Portal film of the boost (1999). Contoured: Anterior tubercle of the anterior atlas arc/atlanto-occipital joint. (B) Simulation film with 
primary gross tumor volumes drawn in 1999.
  A   B
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succumbed to an aggressive NHL, and therefore, no further 
RICNP FU is available.
IMRT cohort
In order to assess the incidence of RICNP in the IMRT era, we 
identified patients at risk treated in our department with normo-
fractionated/slightly hypofractionated (2.0/2.11/2.2 Gy/f) 
IMRT between January, 2002 and December, 2012. All the 
patients were irradiated with 6-MV photons, with 66-70 Gy, 
5 days/week, using simultaneous-integrated boost IMRT 
as previously described (10). The inclusion criteria were as 
follows: Patients with locoregionally controlled disease who 
received >65 Gy to the lower CN region with a FU of at least 
24 months. These criteria were met by 151 patients treated 
with definitive IMRT, with or without additional chemo-
therapy. Focus was on the lower CNs, as they are the CNs most 
exposed to high radiation dose. The patient characteristics are 
summarized in Table I.
The corresponding anatomic ROI was retrospectively 
contoured in the planning CT by B.Y. and reviewed by C.G. 
(Fig. 2). The anatomic ROI was drawn from the base of the skull 
through the carotid sheath above the hyoid bone, where the 
CNs IX-XII are located between the internal jugular vein and 
internal carotid artery down to the thyroid cartilage, which is 
approximately in the upper border of C4 (11). The space in the 
level of 2nd and 3rd cervical vertebrae included the common 
carotid artery inferiorly and internal carotid artery superiorly, 
internal jugular vein and the IX, X, XI and XII cranial nerves. 
Due to the limited resolution of the planning CT, it was not 
possible to draw each of the lower CNs separately.
All the patients were followed up on a weekly basis 
during the RT period by a radiation oncologist. Regular 
FU visits were conducted in our joint clinic (Department of 
Otorhinolaryngology, Head and Neck Surgery, University 
Hospital of Zurich) and, in part, at a private clinic. The 
institutional standards for patient assessment included 
physical examination and flexible fiberoptic endoscopy 
every ~2 months during the first year of FU, every 3 months 
during the second and third years and every 6 months 
during the fourth and fifth years. In case of suspicious 
findings or clinical symptoms, further investigations were 
performed, including magnetic resonance imaging, positron 
emission tomography-CT, or fine-needle aspirations. 
Clinical examination to diagnose or exclude RICNP was 
routinely performed, based on clinical history and physical 
Figure 4. Overall survival curve of intensity-modulated radiation therapy 
cohort. Cum, cumulative.
Figure 5. Dose-volume histogram of the nerve regions of interest (ROIs) in 
the assessed intensity-modulated radiation therapy cohort (see also Fig. 2) 
[absolute ROI volumes: Mean/median 9.4/9.0 cc (range, 5.5-13.9 cc)].
Table I. Patient and treatment parameters.
Parameters Values
Patients, no. 151
Cervical sides at risk, no. 188
Primary tumor location, no.
  Oropharynx 75
  Nasopharynx 27
  Hypopharynx 30
  Supraglottic area 11
  Oral cavity 4
  Glottic 3
  Unknown primary 1
Gender ratio (female:male) 1:3.5
Mean age, years (range) 58 (16-84)
Follow-up, months 71/68 (27-145)
mean/median (range)
T stage, %
  1 11
  2 24
  3 25
  4 39
  Unknown primary 1
N stage, %
  0 6
  1-2b 58
  2c 29
  3 7
Systemic therapy, no. 82
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examination in our Otorhinolaryngology joint clinic. As 
CNP is a clinical disorder with distinct subjective symptoms, 
affected patients were reliably diagnosed during the regular 
FU visits; undetected cases were unlikely in the assessed 
cohort undergoing regular FU.
Systemic chemotherapy was administered in combina-
tion with IMRT when indicated [cisplatin weekly 40 mg/m2 
(82%) and/or cetuximab 400 mg/m2 loading dose followed by 
250 mg/m2 weekly during RT, according to Bonner et al (12)]. 
To date, one of 151 patients in the IMRT cohort has developed 
lower CNP after 6 years post IMRT (see Case report 2). The 
overall survival of the IMRT cohort is depicted in Fig. 4. A 
total of 114 patients with unilateral and 37 patients with bilat-
eral exposure [total: 114+(2x37)=188 ROIs in 151 individuals] 
were included in this analysis. The dose-volume histograms of 
all 188 ROIs are shown in Fig. 5. The absolute volumes of the 
ROIs were mean/median 9.4/9.3 cc (range, 5.5-14.5 cc). The 
mean dose was 65.45 Gy (range, 46.26-75.42 Gy) and the mean 
maximum dose was 75.42 Gy (range, 59.7-108.13 Gy). A total 
of 55, 37 and 8% of the patients were followed up for 5, 7 and 
10 years, respectively. The mean/median duration of FU of the 
entire cohort was 71/68 months (range, 27-145 months).
Discussion
The presented case with bilateral CN XII palsy due to radia-
tion exposure in the pre-IMRT era prompted us to analyze our 
IMRT cohort at risk. There was one (1) RICNP case among 
151 assessed patients treated with definitive IMRT in our 
institution, after a mean FU of 71 months.
There were certain limitations to this analysis, mainly due 
to its retrospective approach and the relatively short observa-
tion time.
A crucial point when evaluating RICNP rates is the duration 
of observation of the assessed cohorts, as the risk for such events 
changes with longer FU. For RT-induced brachial plexopathy, 
the risk was found to be constant over a considerable portion of 
breast cancer patients' life (13). Johansson et al (14) retrospec-
tively analyzed the latency for RT-induced neuropathy in breast 
cancer patients and found that the incidence at 5 years did not 
represent the full spectrum of injuries.
Over the last few years, certain study groups published 
results focusing on RICNP in patients with nasopharyn-
geal (1-4,15) and oropharyngeal cancer (16). In those reports, 
the rate of RICNP ranges between 3.7 and 30.9% (Table II). As 
summarized in Table II, the techniques and doses of RT and 
the frequency of chemotherapy application exhibited signifi-
cant variations, which may be responsible for the wide range of 
RICNP incidence. The median FU time in the aforementioned 
studies ranged between 7.5 and 11.4 years. Rong et al (1) 
reported a mean latency for RICNP of 5.85 years. Kong et al (2) 
demonstrated that, among all patients who developed RICNP, 
~10% developed RICNP during every 5 years. The cumula-
tive incidence for lower RICNP was 5.7, 17.4, 27.1 and 37.3% 
at 5, 10, 15 and 20 years, respectively. Another study group 
focusing on XII CNP reported the development of RICNP in 8 
of the 17 affected patients within the first 50 months following 
RT completion (4).
Several risk factors for RICNP have been described: 
Kong et al (2) identified initial CNP at diagnosis, 
chemotherapy, total radiation dose and upper neck fibrosis as 
independent risk factors for developing RICNP. Luk et al (3) 
also found CNP at diagnosis to be a prognostic factor. In 
our cohort, 82% of the patients received systemic therapy 
and none of the included patients presented with CNP 
prior to treatment initiation. The majority of the studies on 
RICNP included patients prior to the availability of IMRT 
(Table II). IMRT is known to improve the therapeutic ratio 
and/or treatment tolerance in patients with head and neck 
cancer (17,18) by facilitating sparing of normal tissue. In a 
prospective trial analyzing hypofractionated IMRT with 
chemotherapy for nasopharyngeal cancer, Bakst et al (6) only 
reported 4% RICNP.
In conclusion, our results and the general knowledge of the 
tissue sparing ability of IMRT indicate that modern RT tech-
niques may affect the incidence of RICNP by exposing shorter 
parts of the nerves to high radiation doses and by causing less 
extensive muscle and soft tissue fibrosis close to the CNs, 
which was also considered to be partly responsible for the 
pathogenesis of RICNP. Applying IMRT, physicians must bear 
in mind that ‘hot spots’ in CN regions must be avoided (11).
Hypofractctionation >2.11 Gy/f may result in a higher risk for 
RICNP due to hot spots. RT-induced nerve damage is known 
for a potentially long latency till clinical appearance (19).
Modulated tissue-sparing RT techniques may have the 
potential to reduce the incidence of RICNP. Longer FU is 
required to support this hypothesis.
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